Home › Funds › ArrowMark Colorado Holdings LLC › AKTS
ArrowMark Colorado Holdings LLC position in AKTS
AKTIS ONCOLOGY INC · Health Care
ArrowMark Colorado Holdings LLC reported holding 852,159 shares of AKTS (AKTIS ONCOLOGY INC) in its Q3 2026 13F filing — a position valued at US$16.6M, representing 0.79% of its reported portfolio and ranking #24 among its reported holdings. ArrowMark Colorado Holdings LLC has disclosed AKTS holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How ArrowMark Colorado Holdings LLC's AKTS position evolved
ArrowMark Colorado Holdings LLC first disclosed a stake in AKTS in Q1 2026 at 329,471 shares (US$5.9M). The position peaked in Q3 2026 at 852,159 shares, worth US$16.6M. Across 3 filings, ArrowMark Colorado Holdings LLC increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 852,159 shares valued at US$16.6M — an increase of 606,287 shares quarter over quarter.. Notable position changes include a 25% trim in Q2 2026 (shares fell 40% over the following quarter), a 247% increase in Q3 2026 (shares fell 15% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 329.47K | $5.89M | New |
| Q2 2026 | 245.87K | $7.92M | Reduce |
| Q3 2026 | 852.16K | $16.59M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About AKTS and 13F data
AKTS (AKTIS ONCOLOGY INC) is a Health Care company. 130 other funds we track also report a position in AKTS — the largest reported positions include MPM BioImpact LLC (US$155.9M), EcoR1 Capital, LLC (US$93.9M), Blue Owl Capital Holdings LP (US$65.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding AKTS
- MPM BioImpact LLC 4.84M sh · $155.86M · Q2 2026
- EcoR1 Capital, LLC 4.82M sh · $93.93M · Q3 2026
- Blue Owl Capital Holdings LP 3.34M sh · $65.10M · Q3 2026
- RA CAPITAL MANAGEMENT, L.P. 1.31M sh · $42.36M · Q2 2026
- BAKER BROS. ADVISORS LP 996.35K sh · $32.11M · Q2 2026
- Octagon Capital Advisors LP 960.85K sh · $30.97M · Q2 2026
- Merck & Co., Inc. 952.84K sh · $18.55M · Q3 2026
- Avidity Partners Management LP 484.20K sh · $15.61M · Q2 2026
- a16z Capital Management, L.L.C. 415.00K sh · $13.38M · Q2 2026
More on ArrowMark Colorado Holdings LLC
FAQ
How long has ArrowMark Colorado Holdings LLC held AKTS?
ArrowMark Colorado Holdings LLC has disclosed AKTS holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
What is ArrowMark Colorado Holdings LLC's current position in AKTS?
As of Q3 2026, ArrowMark Colorado Holdings LLC holds 852.16K shares of AKTS (AKTIS ONCOLOGY INC), valued at $16.59M, representing 0.79% of its reported portfolio and ranking #24.
Has ArrowMark Colorado Holdings LLC been buying or selling AKTS?
In the latest 13F filing (Q3 2026), ArrowMark Colorado Holdings LLC increased its position in AKTS. The position peaked in Q3 2026 at 852.16K shares.
Which other funds hold AKTS?
Other major institutional holders of AKTS include MPM BioImpact LLC, EcoR1 Capital, LLC, Blue Owl Capital Holdings LP, among 130 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.